Krystal Biotech (NASDAQ:KRYS) Reaches New 12-Month High After Better-Than-Expected Earnings

Krystal Biotech, Inc. (NASDAQ:KRYS) shares hit a new 52-week high during mid-day trading on Wednesday following a stronger than expected earnings report. The stock traded as high as $298.30 and last traded at $287.84, with a volume of 842516 shares traded. The stock had previously closed at $276.45.

The company reported $1.70 earnings per share for the quarter, beating analysts’ consensus estimates of $1.62 by $0.08. The company had revenue of $107.11 million during the quarter, compared to analyst estimates of $105.30 million. Krystal Biotech had a return on equity of 18.69% and a net margin of 52.64%.

Krystal Biotech News Roundup

Here are the key news stories impacting Krystal Biotech this week:

• Positive Sentiment: Q4 beat: Krystal reported $1.70 EPS (vs. $1.62 est.) and $107.1M in VYJUVEK Q4 revenue with 94% gross margin — evidence of profitable commercial traction and stronger net income. Read More.
• Positive Sentiment: Regulatory/designation wins: FDA granted RMAT for KB707 (advanced NSCLC) and Fast Track for KB111 (Hailey‑Hailey disease) — these expedite development and add optionality beyond VYJUVEK. Read More.
• Positive Sentiment: Commercial progress: Over ~660 U.S. reimbursements for VYJUVEK and growing uptake in Germany, France and Japan (90+ patients prescribed across those markets). The company reiterated expansion plans and a strong cash position (~$956M). Read More.
• Positive Sentiment: Analyst uplift: Chardan raised its price target to $323 and reiterated a Buy, adding upward analyst momentum and supporting valuation narratives. Read More.
• Neutral Sentiment: Conference materials and transcripts: The Q4 earnings call transcript, slide deck and investor webcast are available for detailed read‑throughs (helpful for assessing management commentary on growth drivers and expenses). Read More.
• Negative Sentiment: Mixed market reaction / share weakness: Multiple outlets reported KRYS shares slipped (>2%) despite the earnings beat — suggests profit‑taking and short‑term volatility after the print. Read More.
• Negative Sentiment: Reimbursement & launch timing risk in Europe: Pricing negotiations in Germany and France could push meaningful EU revenue later into 2H‑2026/2027, adding execution risk to international growth. Read More.
• Negative Sentiment: Expense / guidance transparency concerns: SG&A rose materially year‑over‑year and management provided non‑GAAP combined R&D+SG&A guidance that excludes stock‑based comp (company says it cannot reliably reconcile)—this can create uncertainty around forward GAAP profitability. Read More.
• Negative Sentiment: Insider selling: Data show material insider sales activity over recent months, which can weigh on investor sentiment even as institutions adjust positions. Read More.

Analysts Set New Price Targets

Several brokerages have recently issued reports on KRYS. Chardan Capital raised their target price on shares of Krystal Biotech from $220.00 to $323.00 and gave the stock a “buy” rating in a report on Wednesday. Zacks Research lowered Krystal Biotech from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 5th. Bank of America lifted their price target on shares of Krystal Biotech from $288.00 to $318.00 and gave the company a “buy” rating in a report on Thursday, January 22nd. HC Wainwright reissued a “buy” rating and set a $310.00 price objective (up from $240.00) on shares of Krystal Biotech in a research report on Friday, January 9th. Finally, The Goldman Sachs Group raised their target price on shares of Krystal Biotech from $206.00 to $327.00 and gave the stock a “buy” rating in a research report on Friday, January 30th. Nine equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $307.22.

Insiders Place Their Bets

In other Krystal Biotech news, CAO Kathryn Romano sold 12,500 shares of the firm’s stock in a transaction on Monday, February 9th. The stock was sold at an average price of $272.14, for a total transaction of $3,401,750.00. Following the completion of the transaction, the chief accounting officer owned 19,318 shares of the company’s stock, valued at approximately $5,257,200.52. This trade represents a 39.29% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction on Thursday, December 4th. The shares were sold at an average price of $220.16, for a total transaction of $5,504,000.00. Following the sale, the insider owned 1,413,711 shares in the company, valued at approximately $311,242,613.76. This trade represents a 1.74% decrease in their position. The disclosure for this sale is available in the SEC filing. 13.70% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Krystal Biotech

Institutional investors and hedge funds have recently made changes to their positions in the business. Soleus Capital Management L.P. boosted its position in shares of Krystal Biotech by 108.9% in the 2nd quarter. Soleus Capital Management L.P. now owns 922,958 shares of the company’s stock worth $126,870,000 after purchasing an additional 481,200 shares in the last quarter. Braidwell LP increased its position in Krystal Biotech by 81.6% during the 2nd quarter. Braidwell LP now owns 727,811 shares of the company’s stock valued at $100,045,000 after buying an additional 327,067 shares in the last quarter. Norges Bank purchased a new position in Krystal Biotech during the fourth quarter valued at $70,159,000. William Blair Investment Management LLC boosted its holdings in Krystal Biotech by 152.1% in the fourth quarter. William Blair Investment Management LLC now owns 376,340 shares of the company’s stock worth $92,783,000 after acquiring an additional 227,038 shares in the last quarter. Finally, Janus Henderson Group PLC grew its stake in shares of Krystal Biotech by 2,078.9% in the fourth quarter. Janus Henderson Group PLC now owns 219,440 shares of the company’s stock worth $54,147,000 after acquiring an additional 209,369 shares during the last quarter. Institutional investors own 86.29% of the company’s stock.

Krystal Biotech Price Performance

The business has a 50 day moving average price of $264.84 and a 200 day moving average price of $208.40. The stock has a market capitalization of $8.22 billion, a PE ratio of 41.36 and a beta of 0.49.

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.